Companies › Vericel
1 active drug program in 2 registered trials: 2 Phase 3; Other; next expected readout Feb 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| autologous cultured chondrocytes on porcine collagen membrane (MACI) autologous chondrocyte implantation on porcine collagen scaffold for cartilage repair | – | Phase 3 | Chondral Defect | Feb 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03588975 | autologous cultured chondrocytes on porcine collagen membrane (MACI) | Phase 3 | Chondral Defect | Other | Feb 2030 |
| NCT06915233 | autologous cultured chondrocytes on porcine collagen membrane (MACI) | Phase 3 | Chondral Defect | Other | Jul 2030 |
Cash and short-term investments of $170m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
No annotated target.
–
Aesculap Biologics Metcela OHB Pediatrics CoNextions Medical ULURU
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.